Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23374635 | 1.00 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL23374594 | 1.00 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL16438632 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL18212487 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL14370057 | 0.93 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL20021298 | 0.84 | — | — | |
| SCHEMBL9801414 | 0.83 | LMNA (0.51) | LMNAALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL3661871 | 0.83 | ALDH1A1 (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL23183278 | 0.82 | LMNA (0.43) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17828063 | 0.80 | LMNA (0.46) | LMNAALDH1A1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210171533-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA | 2020-07-23 | — | — | US | disclosed |
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| US-9849135-B2 | USP14 inhibitors for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849135-B2 | USP14 inhibitors for treating or preventing viral infections | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2528911-B1 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY | HARVARD COLLEGE (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9458104-B2 | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ | PHENEX PHARMACEUTICALS AG (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-21 | — | — | US | disclosed |
| US-8168627-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-8168627-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | ENDORECHERCHE, INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | ENDORECHERCHE, INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-7709516-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709516-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | TP53, BRCA1, MET | LMNA 1109/4885ALDH1A1 4214/4885MAPT 1334/4885 |
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | LMNA 1300/4885ALDH1A1 4165/4885MAPT 821/4885 |
| US-20210147383-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | IKZF2, RPL6, HNRNPR | LMNA 1301/4885ALDH1A1 3947/4885MAPT 3157/4885 |
| US-20130045992-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSMB11, PSME3 | LMNA 1348/4885ALDH1A1 4147/4885MAPT 860/4885 |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | LMNA 4475/4885ALDH1A1 2533/4885MAPT 3944/4885 |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | LMNA 1339/4885ALDH1A1 121/4885MAPT 955/4885 |
| US-20210171533-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPO, MPO, OAT | LMNA 2743/4885ALDH1A1 1258/4885MAPT 132/4885 |
| US-11548870-B2 | Compounds useful as inhibitors of helios protein | IKZF2, RPL6, HNRNPR | LMNA 1301/4885ALDH1A1 3947/4885MAPT 3157/4885 |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | AR, SHBG, CYP17A1 | LMNA 3371/4885ALDH1A1 1718/4885MAPT 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.